New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
08:27 EDTSLXP
theflyonthewall.com: Salix target raised to $35 from $24 at Caris
Caris raised its estimates and target price for Salix due to a higher price point and increased penetration for the company's Xifaxan drug. The firm keeps a Buy rating on the stock. :theflyonthewall.com



News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2010
07:54 EDTSLXP
theflyonthewall.com: Salix recent weakness seems unjustified, says Oppenheimer

Subscribe for More Information :theflyonthewall.com

February 1, 2010
06:30 EDTSLXP
theflyonthewall.com: Salix initiated with a Buy at Jefferies

Subscribe for More Information :theflyonthewall.com

January 26, 2010
12:11 EDTSLXP
theflyonthewall.com: Salix February volatility at 51, April at 77 into FDA meeting
Salix Pharmaceutical is recently up 33c to $28.61. An FDA advisor panel meeting is scheduled on February 23 for Xifaxan in hepatic encephalopathy. Oppenheimer upgraded SLXP to Outperform. Call option volume of 5,730 contracts compares to put volume of 4,821 contracts. February option implied volatility is at 51, April is at 77, July is at 69; verses its 26-week average of 67 according to Track Data, suggesting larger February price movement. :theflyonthewall.com
09:00 EDTSLXP
theflyonthewall.com: On The Fly: Analysts Upgrade Summary

Subscribe for More Information :theflyonthewall.com
06:15 EDTSLXP
theflyonthewall.com: Salix upgraded to Outperform from Perform at Oppenheimer

Subscribe for More Information :theflyonthewall.com